Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Assets Average (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Assets Average for 5 consecutive years, with $738.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets Average rose 29.94% year-over-year to $738.0 million, compared with a TTM value of $738.0 million through Dec 2025, up 29.94%, and an annual FY2025 reading of $672.1 million, up 21.44% over the prior year.
  • Assets Average was $738.0 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $686.7 million in the prior quarter.
  • Across five years, Assets Average topped out at $738.0 million in Q4 2025 and bottomed at $220.8 million in Q2 2022.
  • Average Assets Average over 5 years is $461.6 million, with a median of $483.7 million recorded in 2023.
  • The sharpest move saw Assets Average decreased 25.21% in 2022, then surged 109.99% in 2023.
  • Year by year, Assets Average stood at $242.8 million in 2021, then soared by 89.36% to $459.8 million in 2022, then rose by 9.76% to $504.7 million in 2023, then rose by 12.53% to $567.9 million in 2024, then grew by 29.94% to $738.0 million in 2025.
  • Business Quant data shows Assets Average for KNSA at $738.0 million in Q4 2025, $686.7 million in Q3 2025, and $630.2 million in Q2 2025.